Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,099.20
(
-0.40%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.04
(
4.47%
)
Bitcoin
78,014.25
(
-0.29%
)
News Focus
News Focus
Post# of 257441
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: lgonber post# 193721

Saturday, 07/25/2015 12:10:18 PM

Saturday, July 25, 2015 12:10:18 PM

Post# of 257441

ESPR—thanks for your explanation. So if there are 2 different way of thinking, difficult to foresee what will happen here after news. Would you consider to add at $70?

I’m sitting this one out. ESPR’s valuation doesn’t adequately (IMO) discount the uncertainties pertaining to safety, requirements for a CVOT, and the competitive threat from generic Zetia as well as the PCSK9 drugs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today